Aug 19, 2026 04:05PM
Aug 19, 2026 04:05PM
Aug 6, 2026 07:00AM
Aug 3, 2026 07:00AM
Aug 3, 2026 07:00AM
Jul 9, 2026 07:02AM
Jul 9, 2026 07:00AM Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Jul 6, 2026 12:06PM
Jul 6, 2026 12:05PM
Jul 6, 2026 07:01AM
Jul 6, 2026 07:00AM
Jun 23, 2026 06:40AM
Jun 17, 2026 04:19AM
May 12, 2026 07:00AM Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
May 5, 2026 04:21AM
May 4, 2026 04:30PM
May 4, 2026 04:30PM
May 4, 2026 10:14AM
Apr 10, 2026 06:59AM
Mar 10, 2026 07:00AM
Feb 25, 2026 06:59AM FDA accepts Opus Genetics presbyopia drug application
Feb 25, 2026 06:59AM
Jan 20, 2026 05:06AM
Jan 8, 2026 07:07AM
Jan 8, 2026 07:00AM
Nov 12, 2025 07:00AM
Nov 6, 2025 07:03AM
Nov 6, 2025 07:01AM Opus Genetics raises $23 million in registered direct offering
Nov 6, 2025 07:00AM
Nov 6, 2025 07:00AM
Oct 1, 2025 06:55AM
Sep 30, 2025 07:00AM
Sep 30, 2025 07:00AM
Sep 4, 2025 08:00AM
Sep 4, 2025 08:00AM Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Co
Aug 18, 2025 08:01AM
Aug 18, 2025 08:00AM
Aug 13, 2025 04:30PM
Aug 5, 2025 08:00AM
Jul 23, 2025 08:00AM
Jul 3, 2025 04:30PM
Jun 26, 2025 06:56AM Opus Genetics (IRD) Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint
Jun 26, 2025 06:55AM
Jun 23, 2025 08:00AM
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM
May 15, 2025 08:00AM
May 12, 2025 08:00AM
May 6, 2025 08:03AM Opus Genetics (IRD) Granted FDA RMAT Designation for OPGx-LCA5 Gene Therapy Candidate
May 6, 2025 08:00AM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All